<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385125</url>
  </required_header>
  <id_info>
    <org_study_id>OSHO #73</org_study_id>
    <nct_id>NCT00385125</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL</brief_title>
  <official_title>Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Magdeburg</source>
  <brief_summary>
    <textblock>
      Phase II study for treatment of patients with relapsed or primary refractory aggressive B-
      cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for
      autologous stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II study for treatment of patients with relapsed or primary refractory aggressive B-
      cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for
      autologous stem cell transplantation. Aim is to find response rates and duration of
      combination chemotherapy (bendamustine/rituximab) in patients with relapsed or refractory CD
      20 positive B cell NHL.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2004</start_date>
  <completion_date>August 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>response duration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Lymphoma, High-Grade</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven high grade B-NHL (CD 20 &gt;= 20 % positive)

          -  Age &gt;= 18 years

          -  At least one pretreatment with anthracycline polychemotherapy +/- radiatio:

          -  first relapse nad contraindication for aggressive salvage therapy e.g. high dose
             therapy with autologous stem cell transplantation

          -  second relapse (after aggressive salvage therapy)

          -  patient's refusal of aggressive salvage therapy in first relapse

          -  informed consent

        Exclusion Criteria:

          -  untreated patients

          -  pretreatment with bendamustine

          -  primary CNS- lymphoma

          -  Karnofsky index &lt; 50 (except caused by lymphoma)

          -  HIV positive, hepatitis B or C

          -  serious concurrent disease

          -  non-compensated heart failure (&gt;=NYHA 3)

          -  non-compensated hypertension

          -  renal insufficiency (creatinine &gt; 2.0 mg/dl), not related to lymphoma

          -  hepatic insufficiency with transaminase values greater than 3-fold of normal values
             and/or bilirubin levels &gt; 200 µmol/l, not related to lymphoma

          -  missing compliance respective incapability to comply (e.g.cerebral dysfunction

          -  pregnancy

          -  hematopoetic insufficiency not lymphoma related (leucocyte count &lt;= 2500/µl,
             granulocyte count &lt;= 1000/µl, platelet count &lt;= 80000/µl)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Mohren, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Magdeburg, Department of Hematology and Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Mohren, PD</last_name>
    <phone>0049 231 6713266</phone>
    <email>martin.mohren@medizin.uni-magdeburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Magdeburg, departement of Hematology and Oncology</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Mohren, PD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>October 5, 2006</last_update_submitted>
  <last_update_submitted_qc>October 5, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2006</last_update_posted>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>CD 20 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

